title: Application of Monoterpenoids and their Derivatives for Treatment of Neurodegenerative Disorders.
abstract: Neurodegenerative disorders (NDDs) like Alzheimer's disease, Parkinson's disease and Huntington's disease are a heterogeneous group of disorders with the progressive and severe loss of neurons. There are no full proof cures for these diseases, and only medicines are available that can alleviate some of the symptoms. Developing effective treatments for the NDDs is a difficult but necessary task. Hence, the investigation of monoterpenoids which modulate targets applicable to many NDDs is highly relevant. Many monoterpenoids have demonstrated promising neuroprotective activity mediated by various systems. It can form the basis for elaboration of agents which will be useful both for the alleviation of symptoms of NDDs and for the treatment of diseases progression and also for prevention of neurodegeneration. The further developments including detections of monoterpenoids and their derivatives with high neuroprotective or neurotrophic activity as well as the results of qualified clinical trials are needed to draw solid conclusions regarding the efficacy of these agents.
authors.affiliation: Novosibirsk Institute of Organic Chemistry, Siberian Division, Russian Academy of Sciences, Prospect Akademika Lavrent'eva 9, Novosibirsk, 630090, Russian Federation.|Novosibirsk State University, Street Pirogova 2, Novosibirsk, 630090, Russian Federation.
authors.forename: Konstantin P
authors.initials: KP
authors.lastname: Volcho
authors.affiliation: Novosibirsk Institute of Organic Chemistry, Siberian Division, Russian Academy of Sciences, Prospect Akademika Lavrent'eva 9, Novosibirsk, 630090, Russian Federation.
authors.forename: Sergey S
authors.initials: SS
authors.lastname: Laev
authors.affiliation: King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
authors.forename: Ghulam Md
authors.initials: GM
authors.lastname: Ashraf
authors.affiliation: GALLY International Biomedical Research Consulting LLC., 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, United States.|School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, United States.|Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.|Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation.
authors.forename: Gjumrakch
authors.initials: G
authors.lastname: Aliev
authors.affiliation: Novosibirsk Institute of Organic Chemistry, Siberian Division, Russian Academy of Sciences, Prospect Akademika Lavrent'eva 9, Novosibirsk, 630090, Russian Federation.|Novosibirsk State University, Street Pirogova 2, Novosibirsk, 630090, Russian Federation.
authors.forename: Nariman F
authors.initials: NF
authors.lastname: Salakhutdinov
mesh_terms: D000110:Acetylcholinesterase / Q000737:chemistry / Q000378:metabolism; D000818:Animals; D002545:Brain Ischemia / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D002800:Cholinesterase Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D039821:Monoterpenes / Q000737:chemistry / Q000627:therapeutic use*; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018696:Neuroprotective Agents / Q000737:chemistry / Q000627:therapeutic use*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D002800:Cholinesterase Inhibitors; D039821:Monoterpenes; D018696:Neuroprotective Agents; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D000110:Acetylcholinesterase
keywords: Acetylcholinesterase inhibitors; Alzheimer's disease; Huntington's disease; Parkinson's disease; cannabinoids; monoterpenes; monoterpenoids; neuroprotective activity.